Hormonal
Women with prior gestational diabetes mellitus (pGDM) exhibit significantly lower plasma adiponectin concentrations compared to women with normal glucose tolerance (NGT), independent of body fat mass and insulin sensitivity.
If you have a history of gestational diabetes, your body likely produces less of a protective hormone called adiponectin than women who did not have GDM, even if your weight is normal. This is a known risk factor for developing type 2 diabetes and cardiovascular issues. You should prioritize regular monitoring of your blood sugar and insulin sensitivity, as your body may be more prone to insulin resistance than the general population.
pGDM showed lower (P < 0.0001) plasma adiponectin (6.7 ± 0.2 µg/ml) than NGT (9.8 ± 0.6 µg/ml)... After adjustment for body fat mass, plasma adiponectin remained lower in pGDM (P < 0.004)... CONCLUSIONS — Lower plasma adiponectin concentrations characterize women with previous GDM independently of the prevailing insulin sensitivity or the degree of obesity and are associated with subclinical inflammation and atherogenic parameters.
Why this rating
The study uses a robust design with a frequently sampled intravenous glucose tolerance test (FSIGT) to measure insulin sensitivity and a large enough sample size (89 pGDM vs 19 NGT) to show statistically significant differences (P < 0.0001).
Source
Plasma Adiponectin, Insulin Sensitivity, and Subclinical Inflammation in Women With Prior Gestational Diabetes Mellitus
Christine Winzer et al. · Diabetes Care · 2004
DOI 10.2337/diacare.27.7.1721
More from this paper
- In insulin-resistant women with prior GDM, plasma adiponectin levels decrease further over a 1-year follow-up period, even in the absence of changes in body weight, body fat composition, or glucose tolerance.Good
- Lower plasma adiponectin in women with prior GDM is associated with subclinical inflammation, indicated by higher levels of C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →